Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
BMC Neurology
Published in: BMC Neurology 1/2004

Open Access 01-12-2004 | Research article

Magnetic resonance spectroscopy of normal appearing white matter in early relapsing-remitting multiple sclerosis: correlations between disability and spectroscopy

Authors: Juan Luis Ruiz-Peña, Pilar Piñero, Guillermo Sellers, Joaquín Argente, Alfredo Casado, Jesus Foronda, Antonio Uclés, Guillermo Izquierdo

Published in: BMC Neurology | Issue 1/2004

Login to get access

Abstract

Background

What currently appears to be irreversible axonal loss in normal appearing white matter, measured by proton magnetic resonance spectroscopy is of great interest in the study of Multiple Sclerosis. Our aim is to determine the axonal damage in normal appearing white matter measured by magnetic resonance spectroscopy and to correlate this with the functional disability measured by Multiple Sclerosis Functional Composite scale, Neurological Rating Scale, Ambulation Index scale, and Expanded Disability Scale Score.

Methods

Thirty one patients (9 male and 22 female) with relapsing remitting Multiple Sclerosis and a Kurtzke Expanded Disability Scale Score of 0–5.5 were recruited from four hospitals in Andalusia, Spain and included in the study. Magnetic resonance spectroscopy scans and neurological disability assessments were performed the same day.

Results

A statistically significant correlation was found (r = -0.38 p < 0.05) between disability (measured by Expanded Disability Scale Score) and N-Acetyl Aspartate (NAA/Cr ratio) levels in normal appearing white matter in these patients. No correlation was found between the NAA/Cr ratio and disability measured by any of the other disability assessment scales.

Conclusions

There is correlation between disability (measured by Expanded Disability Scale Score) and the NAA/Cr ratio in normal appearing white matter. The lack of correlation between the NAA/Cr ratio and the Multiple Sclerosis Functional Composite score indicates that the Multiple Sclerosis Functional Composite is not able to measure irreversible disability and would be more useful as a marker in stages where axonal damage is not a predominant factor.
Appendix
Available only for authorised users
Literature
1.
Charcot M: Histologie de la sclerose en plaques. Gaz Hosp. 1868, 141: 554-8.
2.
Ferguson B, Matyszak MK, Esiri MM, Perry VH: Axonal damage in acute multiple sclerosis lesions. Brain. 1997, 120 (pt 3): 393-399. 10.1093/brain/120.3.393.CrossRefPubMed
3.
Trapp BD, Peterson J, Ransohoff RM, Rudick R, Mörk S, Bo L: Axonal transection in the lesions of multiple sclerosis. N Engl J Med. 1998, 338: 278-285. 10.1056/NEJM199801293380502.CrossRefPubMed
4.
Waxman SG: Demyelinating diseases – new pathological insights, new therapeutic targets. N Engl J Med. 1998, 338 (5): 323-325. 10.1056/NEJM199801293380510.PubMed
5.
McDonald WI: Rachelle Fishman – Matthew Moore Lecture. The pathological and clinical dynamics of multiple sclerosis. J Neuropathol Exp Neurol. 1994, 53: 338-343.CrossRefPubMed
6.
Miller DH, Albert PS, Barkhof F, Francis G, Frank JA, Hodgkinson S, Lublin FD, Paty DW, Reingold SC, Simon J: Guidelines for the use of magnetic resonance techniques in monitoring the treatment of multiple sclerosis. US National MS Society Task Force. Ann Neurol. 1996, 39: 6-16.CrossRefPubMed
7.
Filippi M, Paty DW, Kappos L, Barkhof F, Compston DA, Thompson AJ, Zhao GJ, Wiles CM, McDonald WI, Miller DH: Correlations between changes in disability and T2-weighted brain MRI activity in multiple sclerosis: a follow-up study. Neurology. 1995, 45: 255-260.CrossRefPubMed
8.
Thorpe JW, Barker GJ, Jones SJ, Moseley I, Losseff N, MacManus DG, Webb S, Mortimer C, Plummer DL, Tofts PS, et al: Magnetisation transfer ratios and transverse magnetisation decay curves in optic neuritis: correlation with clinical findings and electrophysiology. J Neurol Neurosurg Psychiatry. 1995, 59: 487-492.CrossRefPubMedPubMedCentral
9.
Fu L, Matthews PM, De Stefano N, Worsley KJ, Narayanan S, Francis GS, Antel JP, Wolfson C, Arnold DL: Imaging axonal damage of normal-appearing white matter in multiple sclerosis. Brain. 1998, 121: 103-13. 10.1093/brain/121.1.103.CrossRefPubMed
10.
Rudick R, Antel J, Confavreux C, Cutter G, Ellison G, Fischer J, Lublin F, Miller A, Petkau J, Rao S, Reingold S, Syndulko K, Thompson A, Wallenberg J, Weinshenker B, Willoughby E: Clinical Outcomes assessment in multiple sclerosis. Ann Neurol. 1996, 40: 469-479.CrossRefPubMed
11.
Whitaker JN, McFarland HF, Rudge P, Reingold SC: Outcomes assessments in multiple sclerosis clinical trials: a critical analysis. Mult Scler. 1995, 1: 37-47.PubMed
12.
Fischer JS, Rudick RA, Cutter GR, Reingold SC: The Multiple Sclerosis Functional Composite measure (MSFC): an integrated approach to MS clinical outcome assessment. NMSS Clinical Outcomes Assessments Task Force. Mult Scler. 1999, 5: 244-250. 10.1191/135245899678846168.CrossRefPubMed
13.
Kurtzke JF: Rating neurologic impairment in Multiple Sclerosis (EDSS). Neurology. 1983, 33: 1444-52.CrossRefPubMed
14.
Cutter GR, Baier ML, Rudick RA, Cookfair DL, Fischer JS, Petkau J, Syndulko K, Weinshenker BG, Antel JP, Confavreux C, Ellison GW, Lublin F, Miller AE, Rao SM, Reingold S, Thompson A, Willoughby E: Development of a multiple sclerosis functional composite as a clinical trial outcome measure. Brain. 1999, 122: 871-882. 10.1093/brain/122.5.871.CrossRefPubMed
15.
Kalkers NF, De Groot V, Lazeron RHC, Killestein J, Ader HJ, Barkhof F, Lankhorst GJ, Polman CH: MS functional composite: relation to disease phenotype and disability strata. Neurology. 2000, 54: 1233-1239.CrossRefPubMed
16.
Kalkers NF, Bergers L, De Groot V, Lazeron RH, van Walderveen MA, Uitdehaag BM, Polman CH, Barkhof F: Concurrent validity of the MS functional composite using MRI as a biological disease marker. Neurology. 2001, 56: 215-219.CrossRefPubMed
17.
Barnes D, Munro PM, Youl BD, Prineas JW, McDonald WI: The longstanding MS lesion. A quantitative MRI and electron microscopic study. Brain. 1991, 114: 1271-80.CrossRefPubMed
18.
Truyen L, van Waesberghe JHTM, van Walderveen MAA, van Oosten BW, Polman CH, Hommes OR, Ader HJ, Barkhof F: Accumulation of hypointense lesions (Black Holes) on T1 spin echo MRI correlates with disease progressión in multiple sclerosis. Neurology. 1996, 47: 1469-1476.CrossRefPubMed
19.
van Walderveen MAA, Kamphorst W, Scheltens PH, van Waesberghe JH, Ravid R, Valk J, Polman CH, Barkhof F: Histopathologic correlate of hypointense lesions on T1 weighted spin echoMRI in multiple sclerosis. Neurology. 1998, 50: 1282-1288.CrossRefPubMed
20.
Filippi M, Iannucci G, Tortorella C, Minicucci L, Horsfield MA, Colombo B, Sormani MP, Comi G: Comparision of MS clinical phenotypesusing conventional and magnetization transfer MRI. Neurology. 1999, 52: 588-594.CrossRefPubMed
21.
van Waesberghe JHTM, Kamphorst W, De Groot CJ, van Walderveen MA, Castelijns JA, Ravid R, Lycklama a Nijeholt GJ, van der Valk P, Polman CH, Thompson AJ, Barkhof F: Axonal loss in multiple sclerosis lesions: magnetic resonance imaging insights into substrates of disability. Ann Neurol. 1999, 46: 747-754. 10.1002/1531-8249(199911)46:5<747::AID-ANA10>3.3.CO;2-W.CrossRefPubMed
22.
Werring DJ, Clark CA, Barker GJ, Thompson AJ, Miller DH: Diffusion tensor imaging of lesions and normal appearing white matter in multiple sclerosis. Neurology. 1999, 52: 1626-1632.CrossRefPubMed
23.
Cercignani M, Iannucci G, Rocca MA, Comi G, Horsfield MA, Filippi M: Pathologic damage in MS assessed by Diffusión weighted and magnetization transfer MRI. Neurology. 2000, 54: 1139-1144.CrossRefPubMed
24.
Filippi M, Iannucci G, Cercignani M, Assunta Rocca M, Pratesi A, Comi G: A quantitative study of water diffusion in MS lesions and NAWM using echo planar imaging. Neurology. 2000, 54: 1139-1144.CrossRefPubMed
25.
Birken DL, Oldendorf WH: N-acetyl-L-aspartic acid: a literature review of a compound prominent in 1H-NMR spectroscopic studies of brain. Neurosci Biobehav Rev. 1989, 13: 23-31.CrossRefPubMed
26.
Urenjak J, Williams SR, Gadian DG, Noble M: Proton nuclear magnetic resonance spectroscopy unambiguously identifies different neural cell types. J Neurosci. 1993, 13: 981-9.PubMed
27.
Gideon P, Henriksen O, Sperling B, Christiansen P, Olsen TS, Jorgensen HS, Arlien-Soborg P: Early time course of N acetylaspartate, creatine and phosphocreatine, and compounds containing choline in the brain after acute stroke. A proton magnetic resonance spectroscopy study. Stroke. 1992, 23: 1566-72.CrossRefPubMed
28.
Van der knaap MS, Van der Grond J, Luyten PR, den Hollander JA, Nauta JJ, Valk J: 1H and 31P magnetic resonance spectroscopy of brain degenerative cerebral disorders. Ann Neurol. 1992, 31: 202-11.CrossRefPubMed
29.
Chong WK, Sweeney B, Wilkinson ID, Paley M, Hall-Craggs MA, Kendall BE, Shepard JK, Beecham M, Miller RF, Weller IV, et al: Proton spectroscopy of the brain in HIV infection: correlation withclinical, immunologic and MR imaging findings. Radiology. 1993, 188: 119-24.CrossRefPubMed
30.
Matthews PM, Francis G, Antel J, Arnold DL: Proton magnetic resonance spectroscopy for metabolic characterisation of plaques in multiple sclerosis. Neurology. 1991, 41: 1251-6.CrossRefPubMed
31.
Miller DH, Austin SJ, Connelly A, Youl BD, Gadian DG, McDonald WI: Proton magnetic resonance spectroscopy of an acute and chronic lesion in multiple sclerosis [letter]. Lancet. 1991, 337: 58-9. 10.1016/0140-6736(91)93383-K.CrossRefPubMed
32.
Davie CA, Hawkins CP, Barker GJ, Brennan A, Tofts PS, Miller DH, McDonald WI: Serial proton magnetic resonance spectroscopy in acute multiple sclerosis lesions. Brain. 1994, 117: 49-58.CrossRefPubMed
33.
De Stefano N, Matthews PM, Antel JP, Preul M, Francis G, Arnold D: Chemical pathology of acute demyelinating lesions and its correlation with disability. Ann Neurol. 1995, 38: 901-9.CrossRefPubMed
34.
Arnold DL, Matthews PM, Francis G, Antel J: Proton magnetic resonance spectroscopy of human brain in vivo in the evaluation of multiple sclerosis:assessment of the load of disease. Magn Reson Med. 1990, 14: 154-9.CrossRefPubMed
35.
Husted CA, Goodin S, Hugg JW, Maudsley AA, Tsuruda JS, de Bie SH, Fein G, Matson GB, Weiner MW: Biochemical alterations in multiple sclerosis lesions and normal appearing white matter detected by in vivo 31P and 1H spectroscopic imaging. Ann Neurol. 1994, 36: 157-65.CrossRefPubMed
36.
Narayanan S, Fu L, Pioro E, De Stefano N, Collins DL, Francis GS, Antel JP, Matthews PM, Arnold DL: Imaging of axonal damage in multiple sclerosis: spatial distribution of magnetic resonance imaging lesions. Ann Neurol. 1997, 41: 385-91.CrossRefPubMed
37.
Kapeller P, McLean MA, Griffin CM, Chard D, Parker GJ, Barker GJ, Thompson AJ, Miller DH: Preliminary evidence for neuronal damage in cortical grey matter and normal appearing white matter in short duration relapsing remitting multiple sclerosis: a quantitative MR spectroscopic imaging study. J Neurol. 2001, 248: 131-138. 10.1007/s004150170248.CrossRefPubMed
38.
Kapeller P, Brex PA, Chard D, Dalton C, Griffin CM, McLean MA, Parker GJ, Thompson AJ, Miller DH: Quantitative H-MRS imaging 14 year after presenting with a clinically isolated syndrome suggestive of multiple sclerosis. Mult Scler. 2002, 8 (3): 207-210. 10.1191/1352458502ms822oa.CrossRefPubMed
39.
Sarchielli P, Presciutti O, Tarducci R, Gobbi G, Alberti A, Pelliccioli GP, Chiarini P, Gallai V: Localized magnetic resonance spectroscopy in mainly cortical grey matter of patients with multiple sclerosis. J Neurol. 2002, 249 (7): 902-910. 10.1007/s00415-002-0758-5.CrossRefPubMed
40.
Chard D, Griffin CM, McLean MA, Kapeller P, Kapoor R, Thompson AJ, Miller DH: Brain Metabolites changes in cortical grey and normal appearing white matter in clinically early relapsing remitting multiple sclerosis. Brain. 2002, 125: 2342-2352. 10.1093/brain/awf240.CrossRefPubMed
41.
Davie CA, Barker GJ, Webb S, Tofts PS, Thompson AJ, Harding AE, McDonald WI, Miller DH: Persistent functional deficit in multiple sclerosis and autosomal dominant cerebellar ataxia is associated with axon loss. Brain. 1995, 118: 1583-92.CrossRefPubMed
42.
Matthews PM, Pioro E, Narayanan S, De Stefano N, Fu L, Francis G, Antel J, Wolfson C, Arnold DL: Assessment of lesion pathology in multiple sclerosis using quantitative MRI morphometry and magnetic resonance spectroscopy. Brain. 1996, 119: 715-22.CrossRefPubMed
43.
Davie CA, Barker GJ, Thompson AJ, Tofts PS, McDonald WI, Miller DH: 1H Magnetic resonance spectroscopy of chronic cerebral white matter lesions and normal appearing white matter in multiple sclerosis. J Neurol Neurosurg Psychiatry. 1997, 63: 736-42.CrossRefPubMedPubMedCentral
44.
Fischer JS, Jak AJ, Kniker JE, Rudick RA, Cutter G: Administration and scoring manual for the multiple sclerosis functional composite measure. (MSFC). 1999, New York: Demos
45.
Sipe JC, Knobler RL, Braheny SL, Rice GP, Panitch HS, Oldstone MB: A neurological rating scale (NRS) for use in multiple sclerosis. Neurology. 1984, 34: 1368-1372.CrossRefPubMed
46.
Poser CM, Paty DW, Scheinberg L, McDonald WI, Davis FA, Ebers GC, Johnson KP, Sibley WA, Silberberg DH, Tourtellotte WW: New diagnostic criteria for MS: guideline for research protocols. Ann Neurol. 1983, 13: 227-31.CrossRefPubMed
47.
Lublin FD, Reingold SC: Defining the clinical course of Multiple Sclerosis: results of an international survey. National Muntiple Sclerosis Society (USA) Advisory Committee on Clinical trials of New Agents in Multiple Sclerosis. Neurology. 1996, 46: 907-911.CrossRefPubMed
48.
Goodkin DE, Hertsgaard D, Seminary J: Upper extremity function in multiple sclerosis: improving assessment sensitivity with box and block and nine hole peg test. Arch Phys Med Rehabil. 1988, 69: 850-4.PubMed
49.
Gronwell DMA: Paced auditory serial addition task: a measure of recovery from concussion. Percept Mot Skills. 1977, 44: 367-73.CrossRef
50.
Rooney WD, Goodkin DE, Schuff N, Meyerhoff DJ, Norman D, Weiner MW: H-MRS of normal appearing white matter in multiple sclerosis. Mult Scler. 1997, 3 (4): 231-237.CrossRefPubMed
51.
Leary SM, Davie CA, Parker GJ, Stevenson VL, Wang L, Barker GJ, Miller DH, Thompson AJ: H magnetic resonance spectroscopy of normal appearing white matter in primary progresive multiple sclerosis. J Neurol. 1999, 246 (11): 1023-1026. 10.1007/s004150050507.CrossRefPubMed
52.
Tourbah A, Stievenart JL, Gout O, Fontaine B, Liblau R, Lubetzki C: Localized proton magnetic resonance spectroscopy in relapsing remitting versus secondary progressive multiple sclerosis. Neurology. 1999, 53 (5): 1091-1097.CrossRefPubMed
53.
Tartaglia MC, Narayanan S, De Stefano N, Arnaoutelis R, Antel SB, Francis SJ, Santos AC, Lapierre Y, Arnold DL: Choline is increased in pre lesional normal appearing white matter in multiple. J Neurol. 2002, 249 (10): 1382-1390. 10.1007/s00415-002-0846-6.CrossRefPubMed
54.
Enzinger C, Ropele S, Strasser-Fuchs S, Kapeller P, Schmidt H, Poltrum B, Schmidt R, Hartung HP, Fazekas F: Lower levels of N-Acetilaspartate in Multiple Slerosis Patients with the Apolipoprotein E 4 Allele. Arch Neurol. 2003, 60: 65-70.CrossRefPubMed
55.
Wolinsky JS, Narayana PA, Fenstermacher MJ: Proton magnetic resonance spectroscopy in multiple sclerosis. Neurology. 1990, 40: 1764-9.CrossRefPubMed
56.
Arnold DL, Matthews PM, Francis GS, O Connor J, Antel JP: Proton Magnetic resonance spectroscopic imaging for metabolic characterization of demyelinating plaques. Ann Neurol. 1992, 31: 35-41.CrossRef
57.
Van Hecke P, Marcal G, Johannik K, Demaerel P, Wilms G, Carton H, Baert AL: Human brain proton localized NMR spectroscopy in multiple sclerosis. Magn Reson Med. 1991, 18: 199-206.CrossRefPubMed
58.
Grossman RI, Lenkinski RE, Ramer KN, Gonzalez-Scarano F, Cohen JA: MR Proton spectroscopy in multiple sclerosis. Am J Neuroradiol. 1992, 13: 1535-43.PubMed
59.
De Stefano N, Narayanan S, Francis GS, Arnaoutelis R, Tartaglia MC, Antel JP: Evidence of axonal damege in the early stages of Múltiple sclerosis and its relevance to disability. Arch Neurol. 2001, 58: 65-70. 10.1001/archneur.58.1.65.CrossRefPubMed
60.
Narayana PA, Doyle TJ, Lai D, Wolinsky JS: Serial proton magnetic resonance spectroscopic imaging, contrast-enhanced magnetic resonance imaging, and quantitative lesion volumetry in multiple sclerosis. Ann Neurol. 1998, 43: 56-71.CrossRefPubMed
61.
Pan JW, Hetherington HP, Vaughan JT, Mitchell G, Pohost GM, Whitaker JN: Evaluation of multiple sclerosis by spectroscopic imaging at 4.1 T. Magn Reson Med. 1996, 36: 72-77.CrossRefPubMed
62.
Sarchielli P, Presciutti O, Pelliccioli GP, Tarducci R, Gobbi G, Chiarini P, Alberti A, Vicinanza F, Gallai V: Absolute quantification of brain metabolites by Proton Magnetic resonance spectroscopy in normal appearing white matter of multiple sclerosis patients. Brain. 1999, 122 (pt 3): 513-521. 10.1093/brain/122.3.513.CrossRefPubMed
63.
van Walderveen MA, Barkhof F, Pouwels PJ, van SR, Polman CH, Castelijns JA: Neuronal damage in T1 hypointense multiple sclerosis lesions demostrated in vivo using Proton Magnetic resonance spectroscopy. Ann Neurol. 1999, 46: 79-87. 10.1002/1531-8249(199907)46:1<79::AID-ANA12>3.3.CO;2-0.CrossRefPubMed
64.
Davies SE, Newcombe J, Williams SR, McDonald WI, ClarK JB: Hihg resolution proton MR spectroscopy of multiple sclerosis lesions. J Neurochem. 1995, 64: 742-748.CrossRefPubMed
65.
Barbosa S, Blumhardt LD, Roberts N, Lock T, Edwards RHT: Magnetic resonance relaxation time mapping in multiple sclerosis: normal appearing white matter and the "invisible" lesion load. Magn Reson Imaging. 1994, 12: 33-42. 10.1016/0730-725X(94)92350-7.CrossRefPubMed
66.
Filippi M, Campi A, Dousset V, Baratti C, Martinelli V, Canal N, Scotti G, Comi G: A magnetization transfer imaging study of normal-appearing white matter in multiple sclerosis. Neurology. 1995, 45: 478-482.CrossRefPubMed
67.
Tourbah A, Stievenart JL, Iba-Zizen MT, Zannoli G, Lyon-Caen O, Cabanis EA: In vivo localized NMR proton spectroscopy of normal appearing white matter in patients with multiple sclerosis. J Neuroradiol. 1996, 23: 49-55.PubMed
68.
De Stefano N, Matthews PM, Fu L, Narayanan S, Stanley J, Francis GS, Antel JP, Arnold DL: Axonal damage correlates with disability in patients with relapsing remitting multiple sclerosis. Brain. 1998, 121: 1469-77. 10.1093/brain/121.8.1469.CrossRefPubMed
69.
Mainero C, De Stefano N, Iannucci G, Sormani MP, Guidi L, Federico A, Bartolozzi ML, Comi G, Filippi M: Correlates of MS disability assessed in vivo using aggregates of MR quantities. Neurology. 2001, 56: 1331-1334.CrossRefPubMed
70.
Bonneville F, Moriarty DM, Belina SY, Babb JS, Grossman RI, Gonen O: Whole-Brain N-Acetylaspartate concentration: correlation with T2-weighted lesion volume and Expanded Disability Satatus Scale Score in case of Relapsing-Remiting Multiple Sclerosis. Am J Neuroradiol. 2002, 23: 371-375.PubMed
71.
Sarchielli P, Presciutti O, Tarducci R, Gobbi G, Alberti A, Pelliccioli GP, Orlacchio A, Gallai V: H-MRS in patients with multiple sclerosis undergoing treatment with Interferon B 1a; results of a preliminary study. J Neurol Neurosurg Psychiatry. 1998, 64: 204-212.CrossRefPubMedPubMedCentral
72.
Kalkers NF, Bergers E, Castelijns JA, van Walderveen MA, Bot JC, Ader HJ, Polman CH, Barkhof F: Optimizing the association between disability and biological markers in MS. Neurology. 2001, 57: 1253-1258.CrossRefPubMed
73.
Arnold DL, Riess GT, Matthews PM, Francis GS, Collins DL, Wolfson C, Antel JP: Use of proton magnetic resonance spectroscopy for monitoring disease progression in multiple sclerosis. Ann Neurol. 1994, 36: 76-82.CrossRefPubMed
Metadata
Title
Magnetic resonance spectroscopy of normal appearing white matter in early relapsing-remitting multiple sclerosis: correlations between disability and spectroscopy
Authors
Juan Luis Ruiz-Peña
Pilar Piñero
Guillermo Sellers
Joaquín Argente
Alfredo Casado
Jesus Foronda
Antonio Uclés
Guillermo Izquierdo
Publication date
01-12-2004
Publisher
BioMed Central
Published in
BMC Neurology / Issue 1/2004
Electronic ISSN: 1471-2377
DOI
https://doi.org/10.1186/1471-2377-4-8

Other articles of this Issue 1/2004

BMC Neurology 1/2004 Go to the issue

Research article

Randomised controlled trial of gabapentin in Complex Regional Pain Syndrome type 1 [ISRCTN84121379]

Research article

Homozygosity for a missense mutation in the 67 kDa isoform of glutamate decarboxylase in a family with autosomal recessive spastic cerebral palsy: parallels with Stiff-Person Syndrome and other movement disorders

Research article

Factors associated with in-hospital mortality following intracerebral hemorrhage: a three-year study in Tehran, Iran

Case report

Androgen-induced cerebral venous sinus thrombosis in a young body builder: case report

Research article

Loss of circadian rhythm of blood pressure following acute stroke

Research article

Mechanisms underlying fatigue: a voxel-based morphometric study of chronic fatigue syndrome